Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy

REFERENCES

• Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955;102:157–177.
   PubMed Web of Science ®Google Scholar
• Mathe G, Amiel JL, Schwarzenberg L, et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965;25:1525–1531.
   PubMed Web of Science ®Google Scholar
• Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068–1073.
   PubMed Web of Science ®Google Scholar
• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193(4257):1007–1008.
   PubMed Web of Science ®Google Scholar
• Smith KA, Gilbride KJ, Favata MF. Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells. Nature 1980;287:853–855.
   PubMed Web of Science ®Google Scholar
• Smith KA, Lachman LB, Oppenheim JJ, Favata MF. The functional relationship of the interleukins. Exp Med 1980;151(6):1551–1556.
   Google Scholar
• Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984;223(4643):1412–1414.
   Google Scholar
• Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135(4):2865–2875.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313(23):1485–1492.
   PubMed Web of Science ®Google Scholar
• Silberner J. Therapeutic monoclonal antibody okayed. Science News 1986:407–407.
   Google Scholar
• Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233(4770):1318–1321.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23(10):2346–2357.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nat Rev Clin Oncol 2011;8:577–585.
   PubMed Web of Science ®Google Scholar
• Yee C. Adoptive T cell therapy: addressing challenges in cancer immunotherapy. J Translational Med 2005;3(1):17.
   Google Scholar
• Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29(3):233–240.
   PubMed Web of Science ®Google Scholar
• Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999;163(1):507–513.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Zhao Y, Zheng Z, et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006;66(17):8878–8886.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng Z, Robbins PF, et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005;174:4415–4423.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Zheng Z, Bray R, et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol 2005;175:5799–5808.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314(5796):126–129.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114(3):535–546.
   PubMed Web of Science ®Google Scholar
• Matsui K, Boniface JJ, Steffner P, et al. Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc Natl Acad Sci 1994;91(26):12862–12866.
   Google Scholar
• Mckeithan TW. Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci 1995;92(11):5042–5046.
   Google Scholar
• Gross G, WaksT, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci 1989;86(24):10024–10028.
   PubMed Web of Science ®Google Scholar
• Shirasu N, Kuroki M. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes. Anticancer Res 2012;32:2377–2384
   Google Scholar
• Cheadle EJ, Gornall H, Baldan V, et al. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 2014;257:91–106.
   PubMed Web of Science ®Google Scholar
• Sadelian M, Brentjens R, Riviere I. The basic principle of chimeric antigen receptor design. Cancer Discov 2013;3:388–398.
   Google Scholar
• Kahlon KS, Brown C, Cooper LJ, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004;64(24):9160–9166.
   PubMed Web of Science ®Google Scholar
• Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 2005;28(3):203–211.
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Bagley S, et al. The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 2010;184(12):6938–6949.
   PubMed Web of Science ®Google Scholar
• Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Human Gene Ther 2007;18(8):712–725.
   PubMed Web of Science ®Google Scholar
• Jensen M, Riddell S. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014;257:127–144.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci 1993;90:720–724
   PubMed Web of Science ®Google Scholar
• Brocker T, & Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 1995;181(5):1653–1659.
   PubMed Web of Science ®Google Scholar
• Mueller DL. Mechanisms maintaining peripheral tolerance. Nature Immunol 2010;11(1):21–27.
   PubMed Web of Science ®Google Scholar
• Heuser C, Hombach A, Lösch C, Manista K, & Abken H. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther 2003;10(17):1408–1419.
   Google Scholar
• Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Med 2003;9(3):279–286.
   PubMed Web of Science ®Google Scholar
• Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66(22):10995–11004.
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9(4):271–285.
   PubMed Web of Science ®Google Scholar
• Gramaglia I, Jember A, Pippig SD, et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000;165(6):3043–3050.
   Google Scholar
• Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo. Mol Ther 2009;17(8):1453–1464.
   PubMed Web of Science ®Google Scholar
• Finney HM, Akbar AN, Lawson ADG. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004;172:104–113
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009;183(9):5563–5574.
   PubMed Web of Science ®Google Scholar
• Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4–1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell–mediated tumor eradication. Mol Ther 2010;18(2):413–420.
   PubMed Web of Science ®Google Scholar
• Pulè MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12(5):933– 941.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Heiders J, Foppe M, et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4 (+) T cells. Oncoimmunology 2012;1(4):458–466.
   PubMed Web of Science ®Google Scholar
• Kawabata Y, Hirokawa M, Kitabayashi A, et al. Defective apoptotic signal transduction pathway downstream of caspase-3 in human B-lymphoma cells: a novel mechanism of nuclear apoptosis resistance. Blood 1999;94(10):3523–3530.
   Google Scholar
• Croci DO, Fluck MFZ, Rico MJ, et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunoth 2007;56(11):1687–1700.
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Bollard CM, Vigouroux S, et al. A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene therapy 2004;11(2):81–91.
   Google Scholar
• Zhang L, Kerkar SP, Yu Z, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 2011;19(4):751–759.
   PubMed Web of Science ®Google Scholar
• Fan H, Walters CS, Dunston GM, Tackey R. IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. Cytokine 2002;19(3):126–137.
   Google Scholar
• Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 2011;71(17):5697–5706.
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Goldszmid RS, Muranski P, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011;121(12):4746.
   PubMed Web of Science ®Google Scholar
• Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005;5(7):521–531.
   PubMed Web of Science ®Google Scholar
• Ju DW, Tao Q, Lou G, et al. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 2001;61(9):3735–3740.
   Google Scholar
• Wagner HJ, Sili U, Gahn B, et al. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy 2003;5(3):231–240.
   Google Scholar
• Cheadle EJ, Sheard V, Hombach AAet al., Chimeric antigen receptors for T-cell based therapy. In Antibody Engineering (pp. 645–666). Humana Press. 2012.
   Google Scholar
• Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19(6):747–752.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Ther 2014;21:45–47.
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Al-Kadhimi Z, DiGiusto D, et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 2004;33:83–89.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci 1989;86(24):10024–10028.
   PubMed Web of Science ®Google Scholar
• Fitzer-Attas CJ, Eshhar Z. Tyrosine kinase chimeras for antigen-selective T-body therapy. Adv Drug Del Rev 1998;31(1):171–182.
   Google Scholar
• Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7(1):33–40.
   PubMed Web of Science ®Google Scholar
• Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 1992;217:581–599.
   Google Scholar
• Suerth JD, Schambach A, Baum C. Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol 2012;24(5):598–608.
   PubMed Web of Science ®Google Scholar
• Engels B, Cam H, Schüler T, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003;14(12):1155–1168.
   Google Scholar
• Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999;73(4):2886–2892.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Willemsen R, van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells. Blood 2011;117(1):72–82.
   PubMed Web of Science ®Google Scholar
• Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118(9):3143.
   PubMed Web of Science ®Google Scholar
• Lewinski MK, Bushman FD. Retroviral DNA integration—mechanism and consequences. Adv Genet 2005;55:147–181.
   PubMed Web of Science ®Google Scholar
• Kaufmann KB, Büning H, Galy A, et al. Gene therapy on the move. EMBO Mol Med 2013;5(11):1642–1661.
   PubMed Web of Science ®Google Scholar
• Mátrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther 2010;18(3):477–490.
   PubMed Web of Science ®Google Scholar
• Zennou V, Petit C, Guetard D, et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000;101(2):173–185.
   PubMed Web of Science ®Google Scholar
• Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005;5(4):387.
   PubMed Web of Science ®Google Scholar
• Lewinski MK, Yamashita M, Emerman M, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathogens 2006;2(6):e60.
   Google Scholar
• Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther 2008;8(6):419–429.
   PubMed Web of Science ®Google Scholar
• Pistello M, Vannucci L, Ravani A, et al. Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes. Genet Vaccines Ther 2007;5(1):8.
   Google Scholar
• Vannucci L, Lai M, Chiuppesi F, et al. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 2013;36(1):1–22.
   PubMed Web of Science ®Google Scholar
• Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 2005;5(3):299.
   PubMed Web of Science ®Google Scholar
• Rivera VM, Gao GP, Grant RL, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005;105:1424–1430.
   PubMed Web of Science ®Google Scholar
• Buie LK, Rasmussen CA, Porterfield EC, et al. Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. Invest Ophthalmol Vis Sci 2010;51(1):236–248.
   Google Scholar
• Hicks MJ, Rosenberg JB, De BP, et al. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci Transl Med 2012;4:140ra87. doi:10.1126/scitranslmed.3003611
   PubMed Web of Science ®Google Scholar
• Huang J, Li X, Coelho-dos-Reis JG, et al. An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in mice. PloS One 2014;9(2):e88205.
   PubMed Web of Science ®Google Scholar
• Zhu H, Cao M, Mirandola L, et al. Comparison of efficacy of the disease-specific LOX1- and constitutive cytomegalovirus-promoters in expressing interleukin 10 through adeno-associated virus 2/8 delivery in atherosclerotic mice. PLoS ONE 2014;9(4):e94665. doi:10.1371/journal.pone.0094665
   Google Scholar
• DeKelver RC, Choi VM, Moehle EA, et al. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res 2010;20(8):1133–1142.
   PubMed Web of Science ®Google Scholar
• Meyer M, Wagner E. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum Gene Ther 2006;17(11):1062–1076.
   PubMed Web of Science ®Google Scholar
• Fratantoni JC, Dzekunov S, Singh JC, Liu LN. A non-viral gene delivery system designed for clinical use. Cytotherapy 2003;5:208–210. [PubMed: 12850788]
   Google Scholar
• Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825–833.
   PubMed Web of Science ®Google Scholar
• Ivics Z, Izsvak Z. Transposons for gene therapy. Curr Gene Ther 2006;6(5):593–607.
   PubMed Web of Science ®Google Scholar
• Nakazawa Y, Huye LE, Salsman VS, et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T cells expressing HER2-specific chimeric antigen receptor. Mol Ther 2011;19(12):2133–2143.
   Google Scholar
• Wilson MH, Coates CJ, George AL. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther 2007;15(1):139–145.
   Google Scholar
• Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer research 2008;68(8):2961–2971.
   Google Scholar
• Manuri PVR, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 2010;21(4):427–437.
   Google Scholar
• Nakazawa Y, Huye LE, Salsman VS, et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T cells expressing HER2-specific chimeric antigen receptor. Mol Ther 2011;19(12):2133–2143.
   Google Scholar
• Tavernier G, Andries O, Demeester J, et al. mRNA as gene therapeutic: how to control protein expression. J Control Release 2011;150(3):238–247.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng Z, Cohen CJ, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 2006;13(1):151–159.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010;70(22):9053–9061.
   PubMed Web of Science ®Google Scholar
• Yoon SH, Lee JM, Cho HI, et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther 2009;16(6):489–497.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011;22(12):1575–1586.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T cell populations mediate highly effective adoptive immunotherapy? J Immunother 2012;35(9):651–660.
   PubMed Web of Science ®Google Scholar
• Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008:118(10):294–305.
   Google Scholar
• Gattinoni L, Lugli E, ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17(10):1290–1297.
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112(2):362–373.
   PubMed Web of Science ®Google Scholar
• Kondo M, Sakuta K, Noguchi A, et al. Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008;10(8):842–856.
   PubMed Web of Science ®Google Scholar
• Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human γδ T cells. Science 2005;309(5732):264–268.
   PubMed Web of Science ®Google Scholar
• Todaro M, D'Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by γδ T lymphocytes. J Immunol 2009;182(11):7287–7296.
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T cells in vitro and in SCID mice in vivo. J Immunol 2004;173(11):6767–6776.
   Google Scholar
• Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunology Immunotherapy 2007;56(4):469–476.
   Google Scholar
• Rischer M, Pscherer S, Duwe S, et al. Human γδ T cells as mediators of chimaeric‐receptor redirected anti‐tumour immunity. Br J Haematol 2004;126(4):583–592.
   Google Scholar
• Rogers PR, Matsumoto A, Naidenko O, et al. Expansion of human Vα24+ NKT cells by repeated stimulation with KRN7000. J Immunol Methods 2004;285(2):197–214.
   Google Scholar
• Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of α-galactosylceramide (KRN7000)–pulsed dendritic cells in patients with advanced and recurrent non–small cell lung cancer. Clin Cancer Res 2005;11(5):1910–1917.
   PubMed Web of Science ®Google Scholar
• Kunii N, Horiguchi S, Motohashi S, et al. Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009;100(6):1092–1098.
   PubMed Web of Science ®Google Scholar
• Müller T, Uherek C, Maki G, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008;57(3):411–423.
   PubMed Web of Science ®Google Scholar
• Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009;30(5):656–665.
   PubMed Web of Science ®Google Scholar
• Mekala DJ, Geiger TL. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+ CD25+ T lymphocytes. Blood 2005;105(5):2090–2092.
   Google Scholar
• Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 2009;136(5):1721–1731.
   PubMed Web of Science ®Google Scholar
• Stemberger C, Dreher S, Tschulik C, et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting. PloS One. 2012;7(4):e35798.
   Google Scholar
• Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus–infected subjects. Blood 2000;96(3):785–793.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Cooper LJN, Wu AM, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003;5(2):131–138.
   Google Scholar
• Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B–lineage leukemia effect. Blood 2003;101(4):1637– 1644.
   PubMed Web of Science ®Google Scholar
• Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112(6):2261–2271.
   PubMed Web of Science ®Google Scholar
• Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992;256(5053):105–107.
   PubMed Web of Science ®Google Scholar
• Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18(5–6):385–397.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Popplewell L, Cooper LJ, et al. Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010;16(9):1245–1256.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients. J Clin Invest 2011;121(5): 1822.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells. Blood 2012;119(12):2709–2720.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118(18):4817–4828.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365(8):725–733.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Translational Med 2011;3(95):95ra73–95ra73.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Translational Med 2013;5(177):177ra38–177ra38.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Translational Med 2014;6( 224):224ra25–224ra25.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor–Modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013;21(11):2122–2129.
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1–specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005;105(4):1622–1631.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007;110(7):2620–2630.
   PubMed Web of Science ®Google Scholar
• Cruz CRY, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013;122(17):2965–2973.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013;122(25):4129–4139.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24(13):e20-e22.
   Google Scholar
• Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12(20):6106–6115.
   PubMed Web of Science ®Google Scholar
• Park JR, DiGiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15(4):825–833.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264–1270.
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma. Blood 2011;118(23):6050–6056.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18(4):843–851.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Diouf O, et al. T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma. Cancer Res 2012;72(8 Suppl):Abstract 3500.
   Google Scholar
• Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013;1(1):26–31.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348(3): 255–256.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118(9):3132–3142.
   PubMed Web of Science ®Google Scholar
• Wang GP, Levine BL, Binder GK, et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther 2009;17(5):844–850.
   PubMed Web of Science ®Google Scholar
• Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Translational Med 2012;4(132):132ra53–132ra53.
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014;20(2):119–122.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 2014;26(1):43–49.
   PubMed Web of Science ®Google Scholar
• Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 2014;54:251–272.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29(7):917–924
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013;36(2):133–151.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun 2008;8:8.
   PubMedGoogle Scholar
• Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001;97(5):1508–1510.
   PubMed Web of Science ®Google Scholar
• Mirandola L, Cannon MJ, Cobos E, et al. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol 2011;30(2–3):127–137.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Mirandola L, Yu Y, et al. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother 2011;34(6):490–499.
   Google Scholar
• Chiriva-Internati M, Yu Y, Mirandola L, et al. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate 2012;72(1):2–23.
   Google Scholar
• Chiriva-Internati M, Ferrari R, Yu Y, et al. AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol 2008;140(4):465–468.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Grizzi F, Fiore B, et al. Akap-associated sperm protein overexpression in ovarian cancer: 116. J Investig Med 2007;55(1):S265-S266.
   Google Scholar
• Wen Y, Richardson R, Widgren E, Orand M. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J 357(2001):25–31.
   PubMed Web of Science ®Google Scholar
• Saba R, Saadeh C, Wade R, et al. Selective expression of the Sp17/AKAP4/PTTG1 in NSCLC for detection and therapy. J Clin Oncol 2013;31:(suppl; abstr e18527).
   Google Scholar
• Chiriva-internati M, Wang Z, Salati E, et al. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Scand J Immunol 2002;56(4):429–433.
   PubMedGoogle Scholar
• Grizzi F, Chiriva-Internati M, Franceschini B, et al. Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem 2004;52(4):549–554.
   Google Scholar
• Raymond W, Radhi S, Chiriva-Internati M, et al. The impact of sex on ropporin expression in multiple myeloma patients. J Clin Oncol 2013;31:(suppl; abstr e22052).
   Google Scholar
• McConnachie G, Langeberg LK, Scott JD. AKAP signaling complexes: getting to the heart of the matter. Trends Mol Med 2006;12(7):317–323.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res 2006;4(2): 130–137.
   Google Scholar
• Zhang X, Horwitz GA, Prezant TR, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1999;13(1): 156–166.
   PubMedGoogle Scholar
• Yu R, Melmed S. Oncogene activation in pituitary tumors. Brain Pathol 2001;11(3): 328–341.
   Google Scholar
• Alalawi R, Kim M, Mirandola L, et al. New antigens in non-small cell lung cancer detected both in serology and tissue. Chest J Meeting Abstracts 2011;140(4):938A-938A.
   Google Scholar
• Chiriva-Internati M, Ferrari R, Prabhakar M, et al. The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J Transl Med 2008;6:15.
   Google Scholar
• Hudecek M, Lupo-Stanghellini MT, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013;19(12):3153–3164.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach A, Heuser C, et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004;173(12):7647–7653.
   PubMed Web of Science ®Google Scholar
• Giao PQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013;20(4):289–297. National Center for Biotechnology Information. U.S. National Library of Medicine, Oct. 2013. Web. 18 Feb. 2014.
   Google Scholar
• Gill S, Kalos M. T cell-based gene therapy of cancer. Transl Res 2013;161(4):365–379.
   PubMedGoogle Scholar
• Kong S, Sengupta S, Tyler B, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor–modified T cells. Clin Cancer Res 2012;18(21):5949–5960.
   PubMed Web of Science ®Google Scholar
• Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol 2008;180(1):72–78.
   PubMed Web of Science ®Google Scholar
• Shaffer DR, Savoldo B, Yi Z, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011;117(16):4304–4314.
   PubMed Web of Science ®Google Scholar
• Davies DM, Pereira AC, van der Stegen SJ. et al. Flexible targeting of diverse ErbB dimers that drive tumorigenesis using genetically targeted T cells. Hum Gene Ther 2011;22(10):A118-A118. 140 Huguenot Street, 3rd Fl, New Rochelle, NY 10801 USA: Mary Ann Liebert Inc.
   Google Scholar
• Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013;31(1):71–75.
   PubMed Web of Science ®Google Scholar
• Urbanska K, Lanitis E, Poussin M, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 2012;72(7):1844–1852.
   PubMed Web of Science ®Google Scholar
• Tamada K, Geng D, Sakoda Y, et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res 2012;18(23):6436–6445.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li H, Yang J, et al. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer. Curr Gene Ther 2013;13(1):65–70. Print.
   PubMed Web of Science ®Google Scholar
• Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007;25(11):1298–1306.
   PubMed Web of Science ®Google Scholar
• Trobridge GD, Miller DG, Jacobs MA, et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A 2006;103(5):1498–1503.
   Google Scholar
• Mori Y. Recent topics related to human herpesvirus 6 cell tropism. Cell Microbiol 2009;11(7):1001–1006.
   Google Scholar
• Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005;175(10):7046–7052.
   PubMed Web of Science ®Google Scholar
• Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004;172(7):3983–3988.
   PubMed Web of Science ®Google Scholar
• Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006;24:657–679.
   PubMed Web of Science ®Google Scholar
• Almåsbak H, Rian E, Hoel HJ, et al. Transiently redirected T cells for adoptive transfer. Cytotherapy 2011;13(5):629–640.
   PubMed Web of Science ®Google Scholar
• Wrzesinski C, Paulos CM, Kaiser A, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010;33(1):1–7.
   PubMed Web of Science ®Google Scholar
• Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 2004;1028:104.
   PubMed Web of Science ®Google Scholar
• Gaj T, Gersbach CA, BarbasCFIII. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013;31(7):397–405.
   PubMed Web of Science ®Google Scholar
• Budde LE, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PloS One 2013;8(12):e82742.
   PubMed Web of Science ®Google Scholar
• Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev 2014;258(1):12–29.
   PubMed Web of Science ®Google Scholar
• Gill S, Porter DL. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Exp Opin Biol Therapy 2014;14(1):37–49.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014;257(1):127–144
   PubMed Web of Science ®Google Scholar
• Fedorov VD, Themeli M, Sadelain M. PD-1–and CTLA-4–based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Translational Med 2013;5(215):215ra172–215ra172.
   PubMed Web of Science ®Google Scholar